Search clinical trials for: Provocation OC task (Provoc)

Total 54 results

Baylor College of Medicine
University of Pittsburgh; Brown University

Recruiting

Measuring Automated Behavioral Observations & Vocal Expressions (ABOVE) (ABOVE)

Obsessive-Compulsive Disorder | OCD

United States
Baylor College of Medicine
University of Pittsburgh; Brown University; Butler Hospital

Not yet recruiting

Locating Biomarkers in OCD Through Behavioral Tasks

Obsessive-Compulsive Disorder | OCD

United States
Millennium Pharmaceuticals, Inc.

Completed

A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

Healthy Volunteers

United States
Takeda
Richmond Pharmacology Limited

Completed

Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects

Dose Finding Study
Millennium Pharmaceuticals, Inc.

Completed

A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors

Neoplasms, Advanced Solid

Netherlands
Takeda

Completed

A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) and 60 mg Delayed-release Capsules in Healthy Chinese Participants

Healthy Volunteers

China
Takeda

Completed

A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn

Gastroesophageal Reflux

United States
Takeda

Completed

Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

Gastroesophageal Reflux

United States
Takeda

Withdrawn

Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months

Pediatric Gastroesophageal Reflux Disease

United States, Italy, Israel, Mexico, Poland
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

Gastroesophageal Reflux Disease

United States, Poland, Belgium, Portugal, Italy, Hungary, Mexico, Brazil
Takeda

Completed

Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)

Gastroesophageal Reflux

Belgium, Bulgaria, Poland, Estonia, United Kingdom, Czechia
Takeda

Completed

Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis

Erosive Esophagitis

Japan
Takeda

Completed

Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease

Gastroesophageal Reflux

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants

Neoplasm, Advanced or Metastatic
Takeda

Completed

Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer

Gastric Ulcer

Japan
Takeda

Completed

Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis

Erosive Esophagitis

Japan
Takeda

Completed

Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer

Duodenal Ulcer

Japan
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States
Takeda

Completed

Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
Takeda

Completed

Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease

Gastroesophageal Reflux

United States
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Canada, Czech Republic, Lithuania, Slovakia, Latvia, Estonia, Australia
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
Seoul National University Bundang Hospital

Terminated

The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection

Helicobacter Infection

Korea, Republic of
Takeda

Completed

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis

Erosive Esophagitis

China, Taiwan, Korea, Republic of, Malaysia
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease

United States
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Poland, Bulgaria, India, Canada, Peru, Russian Federation, Australia, New Zealand, Czech Republic, Slovakia, South Africa, Latvia, Lithuania, Colombia, Germany
Takeda

Completed

Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
Takeda

Completed

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection

Duodenal Ulcer

Taiwan, China, Korea, Republic of, Philippines
Takeda

Completed

Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis

Erosive Esophagitis

China, Taiwan, Korea, Republic of, Malaysia
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Poland, Bulgaria, India, South Africa, Canada, Peru, New Zealand, Australia, Lithuania, Slovakia, Hungary, Latvia, Germany, Czech Republic
Takeda

Completed

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection

Gastric Ulcer

Taiwan, China, Korea, Republic of, Philippines
Takeda

Completed

Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

Gastric Ulcers | Duodenal Ulcers

Japan
Takeda

Completed

Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

Gastric Ulcers | Duodenal Ulcers

Japan
Takeda

Completed

Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)

Healthy Volunteers

Japan
Takeda

Completed

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States
Far Eastern Memorial Hospital

Completed

Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit

Ulcer

Taiwan
Takeda

Completed

Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin

Gastric Ulcers | Duodenal Ulcers

Japan
Takeda

Completed

Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin

Gastric Ulcers | Duodenal Ulcers

Japan
Takeda

Completed

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

Healthy Volunteers

United States
Takeda

Completed

Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori

H. Pylori Infection

Japan
Takeda

Completed

TAK-438 Bismuth Drug Interaction Study

Helicobacter Pylori

Korea, Republic of
Tel-Aviv Sourasky Medical Center
Tel Aviv Medical Center

Completed

Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine

Coronary Heart Disease | GI Bleeding

Israel
Emory University
National Cancer Institute (NCI)

Active, not recruiting

RElugolix VErsus LeUprolide Cardiac Trial (REVELUTION)

Biochemically Recurrent Prostate Carcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC... and other conditions

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants

Pain

Australia
Takeda

Completed

A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection

Helicobacter Pylori

China
Takeda

Completed

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

Healthy

United States
Takeda

Completed

A Study of Vonoprazan in Adults With Helicobacter Pylori

Helicobacter Pylori

China
National Taiwan University Hospital

Recruiting

Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection

Helicobacter Pylori Infection

Taiwan
National Cancer Institute (NCI)

Suspended

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Suspended

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Esophageal Adenocarcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma... and other conditions

United States

3

Subscribe